Explanations of growth in health expenditures have restricted attention to the mean. We explain change throughout the distribution of expenditures, providing insight into how growth and its explanation differ along the distribution. We analyse Dutch data on actual health expenditures linked to hospital discharge and mortality registers. Full distribution decomposition delivers findings that would be overlooked by examination of changes in the mean alone. The growth in expenditures on hospital care is strongest at the middle of the distribution and is driven mainly by changes in the distributions of determinants. Pharmaceutical expenditures increase most at the top of the distribution and are mainly attributable to structural changes, including technological progress, making treatment of the highest cost cases even more expensive. Changes in hospital practice styles make the largest contribution of all determinants to increased spending not only on hospital care but also on pharmaceuticals, suggesting important spill over effects.
Introduction
Expenditures on health care continue to increase substantially, both absolutely and relative to national income, throughout most of the developed world. In the Netherlands, for instance, spending on health care increased from 6.6 to 9.9 percent of Gross Domestic Product (GDP) between 1973 and 2008, and real per capita spending almost trebled over this thirty-five year period (OECD, 2011) . Expenditure growth on this scale has profound implications for both health and economic policy. Not surprisingly, accounting for it has been the purpose of much research (e.g. Newhouse, 1992; Getzen, 2000; Mehrotra et al., 2003; Dormont et al., 2006) . This research has either employed aggregate time series or cross-country comparison data to identify the relationship of changes in total spending to determinants at the national level, with the residual being attributed to technological progress (Newhouse, 1992; Gerdtham et al., 1992; O'Connell, 1996; Getzen, 2000) , or it has estimated the relationship of mean expenditure to potential determinants at the individual level, with changes in the relationship being attributed to technological progress and other structural changes (Dormont et al., 2006) . In this paper, we do not merely account for the growth in total (mean) health care expenditure (HCE) but also explain change in its full distribution. This allows us to identify whether the growth is being driven by increased spending at all levels or whether spending on high cost cases is rising relative to the average such that the distribution is becoming even more skewed. We examine the extent to which the drivers of HCE growth vary along the distribution. For example, we can address not only the question of how much population aging is contributing to the growth of mean expenditure but also whether this contribution is stronger at high expenditures than low expenditures and so whether aging stretches or squeezes the distribution. For health insurers and health care providers paid prospectively, it is important to know not only how average expenditures vary with observable characteristics but also how their dispersion differs.
We implement this detailed decomposition of change in the distribution of HCE using very rich individual level insurance claims data on the actual acute care expenditures for two-thirds of the Dutch population over a seven year period from 1998 to 2004 1 . These data are linked to the hospital discharge and mortality registers allowing HCE to be explained not only by demographics, time-todeath and cause-of-death, but also by hospital diagnosis and medical treatment patterns in the hospital.
The latter allows us to open the 'black box' of medical technology by identifying the expenditure growth that can be directly attributed to changes in medical practices in the treatment of specific conditions. We decompose the growth in two large components of HCE -hospital care and pharmaceuticals -separately. Not only the rate of growth but also its explanation turns out to differ substantially between the two. We explore the extent to which changes in hospital practices (e.g. a higher proportion of outpatient care and reduced length of stay) appear to have spill over effects on pharmaceutical spending.
The distribution of HCE may change for two broad types of reason. First, the distributions of the determinants of HCE may change. Through its impact on population health, aging is the most obvious contributor to this source of change. Second, structural changes may alter the way in which given determinants impact on HCE. Medical technology, other changes in medical practice, and changes in health policy at both the micro level of hospitals and insurers, and the macro level of government and regulators are the most likely sources of shifts in the relationship of HCE to its determinants. Most attempts to forecast future trends in HCE, including those that aim to identify the contribution of population aging, estimate a model of HCE and use this to simulate HCE under alternative scenarios about future trends in determinants (e.g. Zweifel et al., 1999; Seshamani, Gray, 2004; Stearns, Norton, 2004; Breyer, Felder, 2006; Lafortune et al., 2007; Häkkinen et al., 2008) . This assumes that the relationship of HCE to its determinants is stable, which is unlikely. At best, these forecasts indicate what will happen in the absence of structural changes within a sector that is noted for technological progress, high government regulation and many policy reforms.
We employ a decomposition method that separates the observed change in the distribution of HCE into the part due to changes in determinants and that due to their changed impact. The size of the second part gives an indication of how wrong a forecast of HCE growth would be if it were made on the assumption of a stable relationship. In this respect, our study is similar to that of Dormont et al. (2006) , who decomposed the growth in French HCE over the period 1992-2000 using a method in the spirit of Oaxaca (1973) and Blinder (1973) . While Dormont et al. explained the change in mean HCE, we decompose the change in the full marginal distribution. This allows us to establish whether the contribution of shifts in determinants, such as aging and population health, is constant across the distribution and also whether the structural shifts in the relationship are more evident for high or low cost cases. We implement this by using distributional regression to generate counterfactual distributions (Chernozhukov et al., 2009 ). This approach delivers findings that could not have been uncovered by a standard decomposition of mean HCE. The growth in expenditures on hospital care is strongest at the middle of the distribution and is driven mainly by changes in the distributions of determinants. In contrast, pharmaceutical expenditures increase most at the top of the distribution and are mainly attributable to structural changes most likely attributable to treatment of the highest cost cases with even more expensive drugs.
Population aging contributes more to the growth of spending on pharmaceuticals than it does to that on hospital care. Aging (and all its correlates) explains 12 percent of the increase in median HCE in the Netherlands between 1998 and 2004. Of all the determinants, changes in hospital practice styles contribute most to the increase not only in spending on hospital care but also on pharmaceuticals. An increased rate of outpatient visits is the single most important of these determinants. The fact that increased reliance on outpatient care can explain greater spending on pharmaceuticals suggests that there are indeed important spill over effects.
In the next section, we describe the most important structural changes in the Dutch health sector within the study period that may have altered the determination of HCE. In the third section, we present the decomposition method employed. The data are described in the fourth section and the results are presented in the fifth. The final section concludes by drawing lessons about the drivers of HCE and acknowledgement of some limitations.
Structural changes in the determination of health care expenditure in the Netherlands

Government policy
Until 2001, the volume of hospital care was constrained by fixed global budgets that enforced an income ceiling on hospitals. Hospitals' activity was further contained by the fact that they were permitted to keep the surplus when the amount of care provided was lower than a priori agreed. Since 1995, hospital specialists have been paid by fixed lump sums rather than fee-for-service. This budget funding successfully contained costs; real HCE grew by an average of 3.7 percent annually and remained fairly constant at 7.7-8.3 percent of GDP over the period 1983 (OECD, 2011 .
Tight budgets alongside population aging and technological progress resulted in lengthening waiting lists for inpatient care. Pressure on the government arose both from public dissatisfaction and rulings from the national court and EU Court that patients have an enforceable right to timely care (European Court of Justice, 2001; Van de Vijsel et al., 2011) . Maximum waiting time standards were developed.
The mounting pressure on the government resulted in a sudden relaxation of hospital budgets in 2001.
Hospitals received posterior compensation when output exceeded their a priori set budget (House of Representatives, 2000) . Although the additional revenue could only be spent on waiting list reduction, in practice, budgets became open-ended. Medical specialist fees were tied to actual production removing financial incentives to under produce. These changes in hospital funding led to substantial increases in HCE, with real spending growth of 6.3, 7.0 and 10.5 percent in , 2002 , respectively (OECD, 2011 . 2 This policy change offers a rare opportunity to trace how an injection of funding gets distributed across patients. We are able to identify how changes in admission rates impacted on not only the level but also the distribution of expenditures.
The sudden relaxation of hospital budgets apparently facilitated a reduction in waiting times. Although waiting lists for acute care only slightly decreased between 1998 and 2002 (2.7 percent), the majority of patients was treated within the allowed waiting period (TCOZ, 2004; Van de Vijsel et al., 2011) .
Hospitalization rates increased disproportionately for the elderly and for treatments with long waiting times (e.g. for cardiovascular, orthopaedic, cataract and plastic surgery).
Medical technology and practice
Although technological progress can, in principle, reduce costs (Cutler, McClellan, 2001; Cutler, 2007) , it tends to introduce more expensive treatments and promotes more widespread use, resulting in higher HCE (Bodenheimer, 2005) , particularly on pharmaceuticals (Dormont et al., 2006; Häkkinen et al., 2008) . To give one example, TNF alpha blockers, which were introduced in 2000, improved the health status of rheumatoid arthritis patients considerably, but increased treatment costs substantially.
In 2010, two TNF alpha blockers were the two most expensive non hospital drugs in the Netherlands, together costing 340 million euro (Health Care Insurance Board, 2011).
Technological progress can also impact on HCE through changes in medical practice. It probably helped facilitate shifts from overnight admissions to day care admissions and policlinic visits (TCOZ, 2004; Borghans et al., 2008) and reduced lengths of stay that occurred between 1998 and 2004. In addition to these substitutions between hospital treatments, there has also been a movement from hospital to GP treatment for some specific diagnoses. An important example is the increased responsibility of GPs for the detection of diabetes within their patient population and its treatment (Rutten et al., 1999; Niessen et al., 2003) .
Integrated care programs, treatment protocols and drug formularies are particularly relevant changes in medical practice. A well-known example of an integrated care program is the specialized stroke unit, which was introduced in the Netherlands from 2000 (Van Exel et al., 2005) . This could either lower or raise treatment costs since average length of stay of admitted stroke patients decreased from 22 to 12 days between 1998 and 2004, while treatment intensified during the shorter stay. The treatment costs of stroke will also have been influenced by GP guidelines to admit all stroke patients to the hospital, which increased hospitalization rates but reduced the average severity of stroke patients admitted.
These are just a few examples of the multitude of policy, technology and medical practice changes that are frequently occurring within the health sector and may alter how health spending responds to determinants such as population demographics and health, which are also changing. A Oaxaca (1973) - Blinder (1973) decomposition could be used to distinguish the contribution of such structural changes to the shift in mean HCE but this would not allow us to examine whether changes at the top of the HCE distribution are explained differently from those at the bottom or middle. It seems likely that, say, technological progress impacts on HCE differentially at different points of the distribution. For example, extremely expensive innovative medicines typically treat serious, high cost conditions resulting in an outward shift of pharmaceutical expenditures given observable determinants that is more pronounced at the top of the distribution.
Decomposition method
A number of methods extending the Oaxaca-Blinder decomposition to explain the difference in full marginal distributions, mostly of wages, have been proposed (e.g. DiNardo et al., 1996; Gosling et al., 2000; Machado, Mata, 2005; O'Donnell et al. 2009; Fortin et al, 2011) . Chernozhukov et al. (2012) provide the inference for methods based on regression models, and introduce one that uses distributional regression (Foresi and Peracchi, 1995) . The decomposition derives from the fact that the marginal distribution of an outcome ( ) Y , in our case HCE, is equal to the integral of its conditional distribution over the distribution of covariates ( ) 
is some link function, which can be specified as logistic, standard normal or the identity, and ( ) y β is a functional parameter that is allowed for vary freely with the value of y . This is very similar to quantile regression, with the essential difference being that the latter models effects on the inverse of the conditional distribution. Both methods permit covariates to change the location, scale and entire shape of the distribution. We use the distributional regression (DR) estimator since quantile regression can provide a poor approximation to a conditional distribution with mass points (Chernozhukov et al, 2012) , which in our application occurs at zero expenditure. DR does not require smoothness of the conditional density, since the approximation is done point wise at the threshold y. 3 A further advantage of DR in this application, given our large sample size, is computational speed.
DR is used to estimate the impact of covariates on the probability that HCE lies below each of 400 
where ε is a residual caused by differences between the empirical and simulated distributions. The first term on the right-hand side is the estimated change in the distribution of HCE attributable to changes in the distributions of its determinants. The second term is the change due to the structural shifts in the relationship of HCE to its determinants. Standard errors are obtained by the bootstrap (100 iterations), the validity of which for this decomposition procedure is established by Chernozhukov et al. (2012) .
We present decompositions of changes in quantiles. These are obtained using the fact that the quantile function is the inverse of the cumulative distribution, (Chernozhukov et al, 2012 
(1)
In addition to the broad distinction between changes in HCE attributable to changes in determinants and the effects of those determinants, we are interested in identifying the specific contributions of changes in population demographics, the disease burden, hospital admission rates, etc. This is done by comparing the first term in (1) (or (2) 
Analogous contributions of a single covariate to changes in quantiles can be derived. This procedure is repeated a number of times to compute the contribution of the change in each (group of) covariate(s).
Since covariates are not changed cumulatively, there is no path dependence in this process. The procedure to resample from the 1998 sample such that a specific covariate is distributed as in 2004 holds correlations between this covariate and the remaining covariates constant. Hence, the distribution of the correlates also changes. Combined with the non-cumulative changes in covariates, this implies that the detailed decomposition does not possess the adding-up property (Fortin et al, 4 Computationally, this is simply, 
where 98 n is the 1998 sample size (Chernozhukov et al, 2012) . 2011) -the sum of the contributions of changes in specific covariates will not equal the aggregate contribution of changes in all covariates. A probability linkage process is used to link these four sources. Linking variables were date of birth, sex, zip code and survival status. Due to incompleteness of date of birth in Vektis, only 49 percent of the sickness fund records could be uniquely identified (N= 9,082,279) . Of the linked individuals, we randomly selected 165,000 for each year to obtain a sample for which computation was feasible. We deliberately oversampled decedents and those with an inpatient admission by a factor of two in order to estimate the effects of covariates related to mortality and inpatient care more precisely.
Data
Iterative proportional fitting (IPF) weights were derived to correct for the sample selection caused by the linking process and deliberate oversampling. IPF corrects the marginal distribution of the weighting variables in the study sample to that of the total sickness fund population (Deming and Stephan, 1940; Bethlehem, 2008) . We use age*sex*decedent status, the linking variables, plus hospitalization status as weighting variables.
Measures of health care expenditure
We decompose change in the distribution of expenditure on: i) acute HCE; ii) hospital and other secondary acute care (hereafter: hospital expenditures); iii) pharmaceuticals. In each case the measure is logarithm of the individual's average monthly spending over the course of the year. 6 The logarithm of expenditure is used because of the extreme skewness of the untransformed distribution. 7 Acute HCE comprises the sum of spending on hospital care, pharmaceuticals, transport, devices, obstetrics and maternity care covered by the basic benefit package. Dental and paramedic care are excluded because they were partly removed from the basic benefit package in 2004 resulting in an apparent drop in the level of these expenditures in 2004. GP expenditures are excluded because, given that GP's were mainly funded on a capitation base during the study period, payments made by the insurer do not correspond to the cost of the GP care provided. Hospital expenditures also include pharmaceutical spending during hospital admissions and include spending on other secondary acute care provided by rehabilitation centres and private clinics that supply treatment covered by public insurance.
Pharmaceutical expenditures refer to spending on pharmaceuticals issued or prescribed at outpatient visits, including those prescribed by GP's.
The influence of technology and other changes in practices to HCE growth can be better captured when correcting for price changes unrelated to changes in treatment patterns, i.e. general and health care specific inflation. Apart from those on pharmaceuticals, all expenditures were deflated to 1998 values using the consumer price index (CPI). Due to several pricing policies, the price of pharmaceuticals decreased by 22 percent in the period 1998 (SFK, 2009 ). Pharmaceutical expenditures were therefore inflated by this proportion. In addition to correcting for general price changes, we control for the Baumol (1967) effect as this raises HCE simply through the rising relative price of health care. We do so by assuming a 0.8 percent annual increase in the cost of labour intensive services only (Douven et al., 2006) . individuals with any expenditure, growth in spending is positive across the entire distribution and is somewhat greater at the centre of the distribution. 
Changes in the empirical distribution of expenditures
Covariates
We use data on demographics, disability, time-to-death (TTD), cause of death, utilisation of hospital care, and hospital diagnosis and procedure to explain the distribution of HCE. Some of these (e.g.
TTD) are potentially endogenous to the expenditures on health care. Since we do not interpret the estimates as causal effects but rather associations that can be used to decompose the change in HCE,
we are not concerned about endogeneity. The largest decreases are in respiratory disease and conditions related to pregnancy and child birth.
Cause-of-death is grouped into 10 categories. There was a very large reduction in deaths due to cardiovascular disease. There was also a fall in the proportion of deaths recorded as due to ill-defined conditions, which is also a category for which there was a steep rise in hospital admissions. The proportion dying from mental and behavioural disorders and a disease of the nervous system/sense organs increased.
Results Figure 3 and Tables III-IV present the decomposition given by equation (2) Figure 3 ). This is true for the entire sample (middle panel of Table III ) and for those with positive hospital expenditure claims (middle panel of Table IV ). The dominance of changes in determinants is 
Detailed decomposition of the contribution of changes in covariates
Equation (3) is used to estimate the contribution of a specific (group of) covariate(s) to the change in the distribution of expenditure. Figure 4 shows the results for the three most interesting groups of covariates, which we label population aging (age composition), disease burden (work disability and cause of death) 10 Figure 5 indicates that, holding the number and type of admissions constant, changes in procedures (e.g. higher proportion of bypass surgery, PTCA and hip replacement) had no impact on hospital expenditures except at the very top end of the distribution. Since some procedures increased while others fell, the implication is that any change in the mix of procedures did not have a noticeable impact on spending.
Tests of changes in relationship of HCE to its determinants
The The joint effect of hospital procedures changed over time, with some increasing in cost and others decreasing. The joint effect of hospital diagnoses on hospital expenditures changed over time, with treatment costs rising for most. Most diagnoses were treated at lower pharmaceutical cost. Remember 11 OLS residuals are not skewed (k=3.08) and so OLS on the log of HCE is an appropriate choice for the second part of this two-part model (Manning and Mullahy, 2001) .
however that pharmaceutical treatment costs of nearly all age groups rose which might indicate that pharmaceutical costs have risen for nearly all population groups regardless of the disease.
Discussion
This is not the first paper to decompose the trend in HCE but it is the first to do so across the full expenditure distribution. This delivers findings that could not have been uncovered by a standard decomposition of mean HCE. Although the growth in acute HCE in the Netherlands was fairly evenly spread across the distribution, this is not true for hospital and pharmaceutical spending separately.
Hospital spending growth, mainly driven by an increased propensity to use, was greatest around the centre of its distribution. This was related to the relatively large increase in outpatient rather than inpatient treatment. By contrast, pharmaceutical spending growth was highest at the higher quantiles, implying that the largest rise occurred among cases that were already very intensive and expensive drug users.
The explanation of the growth in acute HCE differs across the distribution. While changes in the distribution of determinants and the changing impacts of determinants both play an important role, the contribution of the former generally decreases along the distribution while that of the latter increases.
There is a marked difference in the explanation of the rise in hospital and in pharmaceutical expenditures. Hospital expenditure growth is almost entirely explained by changes in determinants.
Their contribution, however, falls at higher quantiles where the contribution of structural changes in the effect of determinants on hospital expenditure growth is apparent. This suggests that technological progress in the hospital sector is targeted at high-cost users and will increase their treatment costs even further. By contrast, changes in both the distribution of determinants and their effects are important in the explanation of pharmaceutical expenditure growth. The greater importance of changes in determinants for hospital expenditure growth is partly related to our selection of determinants that does include changes in hospital practices but not changes in pharmacotherapeutic treatment styles.
Instead, the introduction of new expensive medicines is captured by the contribution of the changing effects of determinants. The higher price of innovative medicines due to patent rights and monopolistic price setting explains the relatively larger rise in the contribution of coefficients at the higher quantiles of the pharmaceutical expenditure distribution. While previous studies identified that increases in drug expenditures are largely driven by technological progress (Dormont et al., 2006; Häkkinen et al., 2008) , we have demonstrated that technological progress accounts mostly for growth at the top end of the drug expenditure distribution. The relatively large contribution of technological progress to drug expenditure growth, especially at the top end of the expenditure distribution, is likely to hold for other countries as well. In more recent year, technological progress seems to have an even larger effect on drug expenditure growth. Consider for instance the introduction of very expensive drugs for cancer treatment (Wilking et al., 2009) .
Changes in determinants that capture population characteristics only marginally contribute to the rise in acute HCE but, among these, population aging is the most important. Changes in hospital practice styles are by far the most important of the changes in determinants. While Dormont et al. (2006) found that changes in medical practices appear to play a dominant role in explaining HCE growth, our rich data allow us to take this further by disentangling the contribution of specific hospital practices.
Increased propensity to use hospital care, in particular outpatient hospital care, explains nearly the entire contribution of changes in determinants to the rise in acute HCE and in hospital spending.
However, changes in other hospital-related factors, have constrained the rise of expenditures in the higher quantiles. Shortened LOS of overnight admissions and an increased propensity to be treated in day care or the policlinic shifted hospital expenditures from the top to the middle of the distribution.
The increased use of day care and policlinics contributed to the rise in pharmaceutical expenditures across the whole distribution, suggesting that hospital care has to some extent been substituted by pharmaceutical care. We cannot, however, conclude anything about the direction of the effect: the introduction of expensive innovative pharmaceuticals may have saved hospital costs, as has been concluded for the US (e.g. Lichtenberg, 2006 Lichtenberg, , 2007 Lichtenberg, , 2009 ), or the less intensive hospital treatment may have shifted costs to the pharmaceutical sector.
Our study has its limitations. First, although we have unique and rich data, the absence of health information on non-hospitalized patients somewhat impedes the interpretation. In the absence of general population health measures, much of the health effect may be captured by the age effect.
Second, changes in the prevalence rates of inpatient hospital diagnoses and changes in the effect of these diagnoses on HCE should be interpreted cautiously. A fall in a specific hospital diagnosis does not necessarily imply a decrease in the overall prevalence of that condition. Similarly, changes in the effect of inpatient hospital diagnoses may not fully capture (changes in) the effect of a disease on acute HCE, hospital expenditures and pharmaceutical. Take the example of outpatient TNF-alpha blockers: while their introduction has increased pharmaceutical treatment costs for rheumatoid arthritis, this cannot be inferred from a change in the effect of a rheumatoid arthritis diagnosis as improved pharmaceutical treatment is likely to have reduced the probability of an inpatient admission for that condition. Third, due to the lack of data on GP spending (funded by a capitation system), we could not explicitly examine possible substitution of hospital treatment by GP treatment, although some of the prescribing consequences are captured indirectly in pharmaceutical spending patterns.
In conclusion, we find that changes in medical practices, in part resulting from technological progress and the relaxation of budgets, were the dominant drivers of acute HCE growth in the Netherlands.
While there is a discernible contribution of population aging to spending growth, it is moderate: population aging could explain 3.5 percentage point of the 29.4 percent growth in median real expenditure. However, its impact cannot be entirely isolated from that of technological progress and the relaxation of hospital budgets. Both developments seem to have disproportionately benefited the elderly given that expenditures on older groups rose more than those on younger groups, and both the expanded waiting list treatments (e.g. cataract and orthopaedic surgery, PTCA) and more liberal prescribing (e.g. of lipid-lowering drugs) were more concentrated among the elderly (Mackenbach et al., 2011) . The latter is a reminder that HCE growth does not merely respond to population aging and developments in medical technology but is the result of deliberate government policy shifts.
Predictions of HCE solely based on changes in population characteristics are very naive and are likely to grossly underestimate future HCE growth. In our case, such projections would have estimated a 6 percent growth at the median instead of the 29 percent growth actually observed between 1998 and Note: Results are derived from the decomposition method defined by equation (2). The total difference is derived from the left hand side of (2), the contribution of changes in covariates from the first term on the right-hand side and the contribution of change in the conditional distribution from the second term on the RHS. 95% confidence intervals are indicated by shading. (2). The total change is derived from the left hand side of (2), the contribution of changes in covariates from the first term on the right-hand side and the contribution of change in the conditional distribution from the second term on the RHS. Bootstrap standard errors were calculated. The decomposition results (5 th and 6 th column) were significant at 5% or less, with the exception of those indicated by superscript ns. A model with a full set of time interactions is used to test the joint significance of a change in the effect of a (group of) covariate(s) on expenditures over time. Null of change in effect (group of) covariate(s) on the probability to use (χ 2 -statistic) or conditional mean expenditures (F-statistic); † p<0.001; ‡ p<0.01; * p<0.05. A positive (negative) change indicates higher (lower) conditional treatment costs associated with the covariate, ceteris paribus Average treatment costs by age increased, except for females aged 15-44 which is due to the removal of oral contraceptives Effect of one overnight admission fell but remained positive; the effect of more than one overnight admission became more positive Increase in average treatment costs for: surgery male genital organs, obstetric surgery; Reduction in average treatment costs for: surgery urinary ways and bladder, PT(C)A, diagnostic endoscopy lower gastrointestinal, other diagnostic procedures Increase in average treatment costs for: infectious disease, colorectal cancer, other malignant neoplasm, mental and behavioral disorders, heart failure, acute respiratory infections, asthma and COPD, rheumatoid arthritis; Reduction in average treatment costs for: diseases of the skin and subcutaneous tissue, conditions originating in the perinatal period, other not allocated and not disease related. Increase in average treatment costs for: osteoarthritis, dorsopathy, conditions originating in the perinatal period; Reduction in average treatment cost for: mental and behavioral disorder, eye and ear disorders, asthma and COPD, other respiratory disease, digestive disease, pregnancy childbirth and contraception, sympthoms signs and illdefined conditions, other not allocated and not disease related. The effect of being institutionalized (ref = individuals living alone) on the probability to use pharmaceuticals decreased, e.g. became more negative. The additional probability to use pharmaceuticals for couples alone compared to individuals living alone decreased over time but remained positive. Positive effect of having one day care admission fell, positive effect of having more than one day care admission increased. 
2004.
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